US2015368361A1PendingUtilityA1

Antibodies against epidermal growth factor receptor (egfr) and uses thereof

47
Assignee: MERRIMACK PHARMACEUTICALS INCPriority: May 4, 2010Filed: Sep 8, 2015Published: Dec 24, 2015
Est. expiryMay 4, 2030(~3.8 yrs left)· nominal 20-yr term from priority
Inventors:Raghida BukhalidMichael FeldhausAnne KingNeeraj KohliEric KraulandUlrik Nielsen
A61P 43/00A61P 35/00C07K 2317/76C07K 16/40C07K 16/2863C07K 2317/515C07K 2317/34A61K 39/39558A61K 2039/507C07K 2317/92C07K 2317/21C07K 2317/51A61K 39/395C07K 16/18
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An isolated monoclonal antibody, or antigen binding fragment thereof, that binds epidermal growth factor receptor (EGFR), wherein the antibody comprises heavy and light chain variable regions, wherein the heavy chain variable region comprises the sequence set forth in SEQ ID NO: 2. 
     
     
         2 . An isolated monoclonal antibody, or antigen binding fragment thereof, that binds epidermal growth factor receptor (EGFR), wherein the antibody comprises heavy and light chain variable regions, wherein the light chain variable region comprises the sequence set forth in SEQ ID NO: 13. 
     
     
         3 . An isolated monoclonal antibody, or antigen binding fragment thereof, that binds epidermal growth factor receptor (EGFR), wherein the antibody comprises heavy and light chain variable regions, wherein the heavy chain variable region comprises the sequence set forth in SEQ ID NO: 2 and the light chain variable regions comprises the sequence set forth in SEQ ID NO: 13. 
     
     
         4 . The monoclonal antibody of  claim 1 , wherein the antibody is a human antibody. 
     
     
         5 . The monoclonal antibody of  claim 1 , wherein the monoclonal antibody is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD and IgE isotype antibodies. 
     
     
         6 . The monoclonal antibody of  claim 1 , wherein the monoclonal antibody is an IgG1 isotype antibody. 
     
     
         7 . The monoclonal antibody of  claim 2 , wherein the antibody is a human antibody. 
     
     
         8 . The monoclonal antibody of  claim 2 , wherein the monoclonal antibody is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD and IgE isotype antibodies. 
     
     
         9 . The monoclonal antibody of  claim 2 , wherein the monoclonal antibody is an IgG1 isotype antibody. 
     
     
         10 . The monoclonal antibody of  claim 3 , wherein the antibody is a human antibody. 
     
     
         11 . The monoclonal antibody of  claim 3 , wherein the monoclonal antibody is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD and IgE isotype antibodies. 
     
     
         12 . The monoclonal antibody of  claim 3 , wherein the monoclonal antibody is an IgG1 isotype antibody. 
     
     
         13 . A composition comprising the monoclonal antibody of any one of  claims 1 - 12  and a pharmaceutically acceptable carrier.

Join the waitlist — get patent alerts

Track US2015368361A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.